Company intelligence
Pangea Bio
Novel Therapies for Central Nervous System Disorders
Biotechnology Research
London, GB
11–50 employees
Founded 2021
2 public signals
About Pangea Bio
Pangea Bio is developing novel therapies that directly activate the TrkB receptor, driving neuronal and synaptic plasticity, and neuroprotection. Dysfunction of the BDNF/TrkB pathway is a hallmark of disorders such as schizophrenia, depression, Alzheimer’s disease, Parkinson’s disease, and glaucoma.
Verified activity
Signals from Pangea Bio
2 published signals
Research & Knowledge
Pangea Bio dosed the first participants in the Phase 1 first-in-human study of OT-003, a small molecule that positively modulates TrkB itself.
Reported by Lars Christian Wilde
Research & Knowledge
Pangea Bio announced that the first participant in the Phase 1 first-in-human clinical trial of OT-003, a small-molecule positive allosteric modulator of TrkB, has been dosed.
Reported by Pangea Bio